NT-proBNP诊断心力衰竭的影响因素研究进展
Research Progress on Influencing Factors of NT-proBNP in the Diagnosis of Heart Failure
DOI: 10.12677/acm.2026.1682828, PDF,    科研立项经费支持
作者: 张皓珺, 张小莹, 高文娟：山东第一医科大学附属省立医院老年医学科，山东 济南；王建春*：山东第一医科大学附属省立医院老年医学科，山东 济南；山东省老年疾病临床医学研究中心，山东 济南
关键词: 心力衰竭；NT-proBNP；生物标志物；影响因素；Heart Failure； NT-proBNP； Biomarker； Influencing Factors
摘要: 心力衰竭(heart failure, HF)是多种心血管疾病的终末阶段，其高患病率与高再住院率使早期诊断与精准风险评估尤为关键。N末端B型利钠肽原(NT-proBNP)因具有较高灵敏度和良好稳定性，已成为心衰诊断与预后评估的核心生物标志物。然而，其循环水平受多种非心衰因素影响，易导致假阳性或假阴性，从而干扰临床决策。本文系统综述了NT-proBNP的生物学特性及其在不同病理生理状态下的变化机制，多角度讨论NT-proBNP的临床应用需突破单一固定阈值模式，结合患者个体特征及多维临床信息进行综合判断。未来应进一步完善特殊人群的分层诊断界值，并结合机器学习与多模态数据整合，推动心衰诊疗向精准医学方向发展。同时，本文进一步结合多重影响因素叠加的模拟临床场景，提出NT-proBNP判读应遵循“先评估验前概率、再识别干扰方向、继而结合动态变化和超声心动图/其他生物标志物验证”的综合决策路径。
Abstract: Heart failure (HF) represents the terminal stage of various cardiovascular diseases. Its high prevalence and readmission rates make early diagnosis and accurate risk assessment particularly crucial. N-terminal pro-B-type natriuretic peptide (NT-proBNP), characterized by high sensitivity and favorable stability, has emerged as a core biomarker for the diagnosis and prognostic assessment of heart failure. Nevertheless, its circulating levels are not specific to heart failure; instead, they are affected by a variety of non-cardiac factors, which tend to induce false-positive or false-negative results and thus impede clinical decision-making. This article systematically reviews the biological characteristics of NT-proBNP and its variation mechanisms under different pathophysiological conditions. From multiple perspectives, it addresses that the clinical application of NT-proBNP necessitates moving beyond the single fixed threshold paradigm, and comprehensive judgments should be made by integrating patients’ individual characteristics and multidimensional clinical information. Future studies are expected to further optimize stratified diagnostic cut-off values for special populations, and integrate machine learning with multimodal data to advance the precision medicine of heart failure diagnosis and treatment. In addition, simulated clinical scenarios with overlapping modifiers are used to propose a practical decision pathway in which pretest probability, direction of confounding, dynamic changes, echocardiography, and complementary biomarkers are integrated when interpreting NT-proBNP results.
文章引用：张皓珺, 张小莹, 高文娟, 王建春. NT-proBNP诊断心力衰竭的影响因素研究进展[J]. 临床医学进展, 2026, 16(8): 574-584. https://doi.org/10.12677/acm.2026.1682828

参考文献

[1] Khan, M.S., Shahid, I., Bennis, A., Rakisheva, A., Metra, M. and Butler, J. (2024) Global Epidemiology of Heart Failure. Nature Reviews Cardiology, 21, 717-734.
https://doi.org/10.1038/s41569-024-01046-6
[2] Teleanu, I.C., Mîrșu-Păun, A., Bejan, C.G. and Stănescu, A.A. (2025) NT-proBNP for Heart Failure Screening in Primary Care in an Eastern European Country: What We Know and Proposed Steps. Epidemiologia, 6, Article 2.
https://doi.org/10.3390/epidemiologia6010002
[3] Lüscher, T.F. (2018) Mechanisms and Outcomes of Heart Failure: From HFpEF, HFmrEF, and HFrEF to Transplantation. European Heart Journal, 39, 1749-1753.
https://doi.org/10.1093/eurheartj/ehy296
[4] Mouzarou, A., Hadjigeorgiou, N., Melanarkiti, D. and Plakomyti, T.E. (2025) The Role of NT-proBNP Levels in the Diagnosis of Hypertensive Heart Disease. Diagnostics, 15, Article 113.
https://doi.org/10.3390/diagnostics15010113
[5] 孙思, 杨晓伟, 马盈心. 血清NT-proBNP､sST2联合检测在慢性心力衰竭诊断中的应用价值[J]. 生命科学仪器, 2026, 24(1): 28-30.
[6] Birrell, H., Isles, C., Fersia, O., et al. (2024) Assessment of the Diagnostic Value of NT-proBNP in Heart Failure with Preserved Ejection Fraction. The British Journal of Cardiology, 31, Article 2.
[7] Çelik, A., Öztürk, G.Z., Çavuşoğlu, Y., Ardıç, C., Nalbantgil, S., Arıca, S., et al. (2025) Guideline for the Use of Natriuretic Peptides in the Early Diagnosis and Management of Heart Failure in Primary Care (Joint Consensus Report by the Eurasian Society of Heart Failure and the Turkish Association of Family Medicine). Balkan Medical Journal, 42, 94-107.
https://doi.org/10.4274/balkanmedj.galenos.2025.2024-12-110
[8] Truyen, T.T.T.T., Pham, V.N.A. and Nguyen, H.T. (2026) Beyond Cardiac Risk Factors: Non-Cardiovascular Comorbidities in Sudden Cardiac Death Prediction. Frontiers in Cardiovascular Medicine, 13, Article 1728987.
https://doi.org/10.3389/fcvm.2026.1728987
[9] Cao, Z., Jia, Y. and Zhu, B. (2019) BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine. International Journal of Molecular Sciences, 20, Article 1820.
https://doi.org/10.3390/ijms20081820
[10] Kerkelä, R., Ulvila, J. and Magga, J. (2015) Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events. Journal of the American Heart Association, 4, e002423.
https://doi.org/10.1161/jaha.115.002423
[11] Semenov, A.G., Tamm, N.N., Seferian, K.R., Postnikov, A.B., Karpova, N.S., Serebryanaya, D.V., et al. (2010) Processing of Pro-B-Type Natriuretic Peptide: Furin and Corin as Candidate Convertases. Clinical Chemistry, 56, 1166-1176.
https://doi.org/10.1373/clinchem.2010.143883
[12] Lewis, L.K., Raudsepp, S.D., Prickett, T.C.R., Yandle, T.G., Pemberton, C.J. and Richards, A.M. (2020) ProBNP Processing Is Decreased by Obesity in Patients with Heart Failure. Annals of Translational Medicine, 8, Article 135.
https://doi.org/10.21037/atm.2019.12.81
[13] Parcha, V. and Arora, P. (2019) Glycosylation of Natriuretic Peptides in Obese Heart Failure: Mechanistic Insights. Annals of Translational Medicine, 7, Article 611.
https://doi.org/10.21037/atm.2019.10.59
[14] Dalal, J., Chandra, P., Ray, S., Hazra, P.K., Hiremath, J., Kumar, V., et al. (2023) Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists. Cardiology and Therapy, 12, 445-471.
https://doi.org/10.1007/s40119-023-00323-8
[15] Rørth, R., Jhund, P.S., Yilmaz, M.B., Kristensen, S.L., Welsh, P., Desai, A.S., et al. (2020) Comparison of BNP and NT-proBNP in Patients with Heart Failure and Reduced Ejection Fraction. Circulation: Heart Failure, 13, e006541.
https://doi.org/10.1161/circheartfailure.119.006541
[16] Ruiz-Franco, M.L., Guevara-Sánchez, E., Amaya-Pascasio, L., Quesada-López, M., Arjona-Padillo, A., García-Torrecillas, J.M., et al. (2023) N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated with Post-Stroke In-Hospital Complications. Journal of Personalized Medicine, 13, Article 474.
https://doi.org/10.3390/jpm13030474
[17] Weber, M. and Hamm, C. (2006) Role of B-Type Natriuretic Peptide (BNP) and NT-proBNP in Clinical Routine. Heart, 92, 843-849.
https://doi.org/10.1136/hrt.2005.071233
[18] Kanyal, S., Das, A., Bashir, A.M.D., et al. (2025) N‑Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) as a Biomarker in Heart Failure with Preserved Ejection Fraction (HFpEF) versus Heart Failure with Reduced Ejection Fraction (HFrEF): The Way Forward in the Age of Proteomics. Cureus, 17, e94162.
https://doi.org/10.7759/cureus.94162
[19] Fuat, A., Murphy, J.J., Hungin, A.P.S., et al. (2006) The Diagnostic Accuracy and Utility of a B-Type Natriuretic Peptide Test in a Community Population of Patients with Suspected Heart Failure. The British Journal of General Practice: The Journal of the Royal College of General Practitioners, 56, 327-333.
[20] Qian, C., Liu, J. and Liu, H. (2024) Targeting Estrogen Receptor Signaling for Treating Heart Failure. Heart Failure Reviews, 29, 125-131.
https://doi.org/10.1007/s10741-023-10356-9
[21] Kuroski de Bold, M.L. (1999) Estrogen, Natriuretic Peptides and the Renin-Angiotensin System. Cardiovascular Research, 41, 524-531.
https://doi.org/10.1016/s0008-6363(98)00324-1
[22] 吴志俊, 金玮, 张凤如, 等. 利钠肽家族基因与心血管疾病研究新进展[J]. 遗传, 2012, 34(2): 127-133.
[23] Moro, C. and Berlan, M. (2006) Cardiovascular and Metabolic Effects of Natriuretic Peptides. Fundamental & Clinical Pharmacology, 20, 41-49.
https://doi.org/10.1111/j.1472-8206.2005.00379.x
[24] Baldassarre, S., Fragapani, S., Panero, A., Fedele, D., Pinach, S., Lucchiari, M., et al. (2017) NTproBNP in Insulin-Resistance Mediated Conditions: Overweight/Obesity, Metabolic Syndrome and Diabetes. the Population-Based Casale Monferrato Study. Cardiovascular Diabetology, 16, Article No. 119.
https://doi.org/10.1186/s12933-017-0601-z
[25] Chitsazan, M., Parekh, J.K., Kosyakovsky, L.B., Nemeth, S.M., Lau, E.S., Januzzi, J.L., et al. (2025) Natriuretic Peptide Cut Points for Heart Failure Classification in Individuals with and without Obesity. Circulation: Heart Failure, 18, e013112.
https://doi.org/10.1161/circheartfailure.125.013112
[26] 朱迎春, 白寿军, 姬婷婷, 等. 血清sST2､NT-proBNP､hs-TnT检测在慢性心肾综合征中的应用价值[J]. 检验医学与临床, 2024, 21(24): 3616-3620.
[27] Tirmenstajn-Jankovic, B., Dimkovic, N., Perunicic-Pekovic, G., et al. (2013) Anemia Is Independently Associated with NT-proBNP Levels in Asymptomatic Predialysis Patients with Chronic Kidney Disease. Hippokratia, 17, 307-312.
[28] McCallum, W., Tighiouart, H., Kiernan, M.S., Huggins, G.S. and Sarnak, M.J. (2020) Relation of Kidney Function Decline and NT-proBNP with Risk of Mortality and Readmission in Acute Decompensated Heart Failure. The American Journal of Medicine, 133, 115-122.e2.
https://doi.org/10.1016/j.amjmed.2019.05.047
[29] Fu, S., Yi, S., Liu, Y., Zhu, B., et al. (2013) The Ability of NT-proBNP to Detect Chronic Heart Failure and Predict All-Cause Mortality Is Higher in Elderly Chinese Coronary Artery Disease Patients with Chronic Kidney Disease. Clinical Interventions in Aging, 8, 409-417.
https://doi.org/10.2147/cia.s42700
[30] Berthelot, E., Bailly, M.T., Lehova, X.C., Rahmani, M.E.B., Bounab, R., Mewton, N., et al. (2024) Setting the Optimal Threshold of NT-proBNP and BNP for the Diagnosis of Heart Failure in Patients over 75 Years. ESC Heart Failure, 11, 3232-3241.
https://doi.org/10.1002/ehf2.14894
[31] Gromadziński, L. and Pruszczyk, P. (2014) Echocardiographic Changes in Patients with Stage 3-5 Chronic Kidney Disease and Left Ventricular Diastolic Dysfunction. Cardiorenal Medicine, 4, 234-243.
https://doi.org/10.1159/000369106
[32] Khan, I., Khan, Z.A., Zaidi, M., et al. (2025) Spectrum of Echocardiography Findings in Patients with End-Stage Renal Disease. Journal of Health, Wellness and Community Research, 2025, e715.
https://doi.org/10.61919/yr4pmc71
[33] Zoccali, C., Mark, P.B., Sarafidis, P., Agarwal, R., Adamczak, M., Bueno de Oliveira, R., et al. (2023) Diagnosis of Cardiovascular Disease in Patients with Chronic Kidney Disease. Nature Reviews Nephrology, 19, 733-746.
https://doi.org/10.1038/s41581-023-00747-4
[34] 吐尔逊江·吾甫尔, 艾力江·阿不力米提. 射血分数降低的心衰与射血分数保留的心衰临床特征分析[J]. 世界最新医学信息文摘, 2016, 16(21): 97.
[35] 李丽, 赵文萍. sST2联合NT-proBNP评估ARNI干预射血分数中间值的心力衰竭患者预后价值分析[J]. 中国循证心血管医学杂志, 2021, 13(1): 85-89.
[36] Karakasis, P., Vlachakis, P.K., Theofilis, P., Ktenopoulos, N., Patoulias, D., Fyntanidou, B., et al. (2025) Atrial Cardiomyopathy in Atrial Fibrillation: A Multimodal Diagnostic Framework. Diagnostics, 15, Article 1207.
https://doi.org/10.3390/diagnostics15101207
[37] Jones, N.R., Taylor, K.S., Ordóñez-Mena, J.M., Goyder, C.R., Hobbs, F.D.R. and Taylor, C.J. (2025) NT-proBNP Testing for Heart Failure Diagnosis in People with Atrial Fibrillation: A Diagnostic Accuracy Study. PLOS Medicine, 22, e1004550.
https://doi.org/10.1371/journal.pmed.1004550
[38] Zdravkovic, V., Mladenovic, V., Colic, M., Bankovic, D., Lazic, Z., Petrovic, M., et al. (2013) NT-proBNP for Prognostic and Diagnostic Evaluation in Patients with Acute Coronary Syndromes. Kardiologia Polska, 71, 472-479.
https://doi.org/10.5603/kp.2013.0093
[39] Chouvarine, P., Legchenko, E., Geldner, J., Riehle, C. and Hansmann, G. (2019) Hypoxia Drives Cardiac miRNAs and Inflammation in the Right and Left Ventricle. Journal of Molecular Medicine, 97, 1427-1438.
https://doi.org/10.1007/s00109-019-01817-6
[40] Humayra, S., Yahya, N., Ning, C.J., Mohd Raffali, M.A.A.B., Mir, I.A., Mohamed, A.L., et al. (2025) Clinical Significance of NT-proBNP as a Predictive Biomarker of Depressive Symptoms in Cardiac Patients. Frontiers in Cardiovascular Medicine, 12, Article 1439520.
https://doi.org/10.3389/fcvm.2025.1439520
[41] Chang, W.T., Shih, J.Y., Hong, C.S., et al. (2021) Right Ventricular Expression of NT-proBNP Adds Predictive Value to Reveal Score in Patients with Pulmonary Arterial Hypertension. ESC Heart Failure, 8, 3082-3092.
https://doi.org/10.1002/ehf2.13410
[42] Kaszuba, E., Wagner, B., Odeberg, H. and Halling, A. (2013) Using NT-proBNP to Detect Chronic Heart Failure in Elderly Patients with Chronic Obstructive Pulmonary Disease. ISRN Family Medicine, 2013, 1-5.
https://doi.org/10.5402/2013/273864
[43] Wei, X., Yu, N., Ding, Q., Ren, J., Mi, J., Bai, L., et al. (2018) The Features of AECOPD with Carbon Dioxide Retention. BMC Pulmonary Medicine, 18, Article No. 124.
https://doi.org/10.1186/s12890-018-0691-8
[44] Su, X., Lei, T., Yu, H., Zhang, L., Feng, Z., Shuai, T., et al. (2023) NT-proBNP in Different Patient Groups of COPD: A Systematic Review and Meta-Analysis. International Journal of Chronic Obstructive Pulmonary Disease, 18, 811-825.
https://doi.org/10.2147/copd.s396663
[45] Li, N., Zhang, Y., Fan, S., et al. (2013) BNP and NT-proBNP Levels in Patients with Sepsis. Frontiers in Bioscience, 18, 1237-1243.
https://doi.org/10.2741/4175
[46] Yang, W., Cao, Y., Li, J., Zhang, X., Liu, X., Tian, Y., et al. (2025) Pathogenesis and Treatment Strategies of Sepsis-Induced Myocardial Injury: Modern and Traditional Medical Perspectives. International Journal of Biological Sciences, 21, 3478-3504.
https://doi.org/10.7150/ijbs.111288
[47] Li, H., Chen, C. and Wang, D.W. (2021) Inflammatory Cytokines, Immune Cells, and Organ Interactions in Heart Failure. Frontiers in Physiology, 12, Article 695047.
https://doi.org/10.3389/fphys.2021.695047
[48] Wang, J., Ji, W., Xu, Z. and Pan, T. (2016) Clinical Significance of Plasma Levels of Brain Natriuretic Peptide and Cardiac Troponin T in Patients with Sepsis. Experimental and Therapeutic Medicine, 11, 154-156.
https://doi.org/10.3892/etm.2015.2863
[49] Xu, C., Zheng, A., He, T. and Cao, Z. (2020) Brain-Heart Axis and Biomarkers of Cardiac Damage and Dysfunction after Stroke: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 21, Article 2347.
https://doi.org/10.3390/ijms21072347
[50] Wang, M. and Peng, Y. (2022) Advances in Brain-Heart Syndrome: Attention to Cardiac Complications after Ischemic Stroke. Frontiers in Molecular Neuroscience, 15, Article 1053478.
https://doi.org/10.3389/fnmol.2022.1053478
[51] Liu, R., Chen, G., Zhao, N. and Yue, W. (2025) Predictive Value of NT-proBNP for Functional Outcome of Ischemic Stroke without Cardiac Disease: A Prospective, Observational Study. Neuropsychiatric Disease and Treatment, 21, 129-140.
https://doi.org/10.2147/ndt.s488574
[52] Watts, D., Gaete, D., Rodriguez, D., Hoogewijs, D., Rauner, M., Sormendi, S., et al. (2020) Hypoxia Pathway Proteins Are Master Regulators of Erythropoiesis. International Journal of Molecular Sciences, 21, Article 8131.
https://doi.org/10.3390/ijms21218131
[53] Zhang, H., Li, X., Zhang, N. and Tian, L. (2023) Effect of Thyroid Dysfunction on N-Terminal Pro-B-Type Natriuretic Peptide Levels: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 14, Article 1083171.
https://doi.org/10.3389/fendo.2023.1083171
[54] Zhao, X., Zhang, R., Jiang, H., Liu, K., Ma, C., Bai, M., et al. (2021) Combined Use of Low T3 Syndrome and NT-proBNP as Predictors for Death in Patients with Acute Decompensated Heart Failure. BMC Endocrine Disorders, 21, Article No. 140.
https://doi.org/10.1186/s12902-021-00801-x
[55] Ferreira, J.P., Oliveira, A.C., Saraiva, F., et al. (2026) Design, Rationale, and Methods of the INITIATE-HFrEF Trial: ARNI and SGLT2 Inhibitors Sequencing in HFrEF. JACC: Advances, 5, Article 102589.
https://doi.org/10.1016/j.jacadv.2026.102589
[56] Ibrahim, N.E. and Januzzi, J.L. (2018) The Future of Biomarker-Guided Therapy for Heart Failure after the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study. Current Heart Failure Reports, 15, 37-43.
https://doi.org/10.1007/s11897-018-0381-0
[57] Langenickel, T.H. and Dole, W.P. (2012) Angiotensin Receptor-Neprilysin Inhibition with LCZ696: A Novel Approach for the Treatment of Heart Failure. Drug Discovery Today: Therapeutic Strategies, 9, e131-e139.
https://doi.org/10.1016/j.ddstr.2013.11.002
[58] Krum, H. (2015) Prospective Comparison of ARNi with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF): Paragon of a Study or Further Investigation Paramount? Circulation, 131, 11-12.
https://doi.org/10.1161/circulationaha.114.013887
[59] Mueller, C., McDonald, K., de Boer, R.A., Maisel, A., Cleland, J.G.F., Kozhuharov, N., et al. (2019) Heart Failure Association of the European Society of Cardiology Practical Guidance on the Use of Natriuretic Peptide Concentrations. European Journal of Heart Failure, 21, 715-731.
https://doi.org/10.1002/ejhf.1494
[60] Pieske, B., Tschöpe, C., de Boer, R.A., Fraser, A.G., Anker, S.D., Donal, E., et al. (2019) How to Diagnose Heart Failure with Preserved Ejection Fraction: The HFA-PEFF Diagnostic Algorithm: A Consensus Recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 40, 3297-3317.
https://doi.org/10.1093/eurheartj/ehz641
[61] Nagueh, S.F., Smiseth, O.A., Appleton, C.P., Byrd, B.F., Dokainish, H., Edvardsen, T., et al. (2016) Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography, 29, 277-314.
https://doi.org/10.1016/j.echo.2016.01.011
[62] Obokata, M., Reddy, Y.N.V., Pislaru, S.V., Melenovsky, V. and Borlaug, B.A. (2017) Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure with Preserved Ejection Fraction. Circulation, 136, 6-19.
https://doi.org/10.1161/circulationaha.116.026807
[63] Hawkins, N.M., Petrie, M.C., Jhund, P.S., Chalmers, G.W., Dunn, F.G. and McMurray, J.J.V. (2009) Heart Failure and Chronic Obstructive Pulmonary Disease: Diagnostic Pitfalls and Epidemiology. European Journal of Heart Failure, 11, 130-139.
https://doi.org/10.1093/eurjhf/hfn013
[64] Chang, H.C., Kuo, L., Chung, F.P., et al. (2023) Pitfalls for the Non-Invasive Diagnosis of Wild-Type Transthyretin Amyloid Cardiomyopathy in a Young Adult: A Case Report. European Heart Journal—Case Reports, 7, ytad308.
https://doi.org/10.1093/ehjcr/ytad308
[65] Quek, S., Zill-E-Huma, R., Andrews, M., et al. (2025) Usefulness of Brain-Type Natriuretic Peptide (BNP) Levels in Pregnancy. Obstetric Medicine, 2025, 1753495X251398074.
[66] Iacoviello, M., Santamato, V., Pagano, A. and Marengo, A. (2025) Interpretable AI-Driven Multi-Objective Risk Prediction in Heart Failure Patients with Thyroid Dysfunction. Frontiers in Digital Health, 7, Article 1583399.
https://doi.org/10.3389/fdgth.2025.1583399

为你推荐